NCT01521585View on ClinicalTrials.gov

A Phase II Safety and Tolerability Study With SEN0014196

PHASE2CompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Huntington's Disease
Interventions
DRUG

SEN0014196

50 mg oral once daily tablet

DRUG

SEN0014196

200 mg oral once daily tablet

DRUG

Placebo

oral once daily tablet

Trial Locations (1)

48149

Dept. of Neurology, University of Münster, Münster

All Listed Sponsors
lead

Siena Biotech S.p.A.

INDUSTRY

NCT01521585 - A Phase II Safety and Tolerability Study With SEN0014196 | Biotech Hunter | Biotech Hunter